Welcome to our dedicated page for NORD ANGLIA ED news (Ticker: NORD), a resource for investors and traders seeking the latest updates and insights on NORD ANGLIA ED stock.
Nordicus Partners Corporation (OTCQB: NORD) issues frequent updates about its activities as a business accelerator, holding company, and financial consulting company focused on Nordic and U.S. life sciences. Its news flow centers on the progress of its preclinical biotech subsidiaries, corporate developments, and capital markets actions.
Readers of the NORD news page can follow detailed announcements from Orocidin A/S, Bio-Convert A/S, and NoviThera ApS, all of which are owned or majority owned by Nordicus. Recent releases describe Orocidin’s preclinical efficacy and toxicity studies for its periodontitis candidate QR-01, including animal model results and the development of a cGMP-compliant manufacturing process in collaboration with Syngene International Limited. Bio-Convert’s updates cover regulatory feedback from the Danish Medicines Agency for QR-02 in oral leukoplakia and its proprietary mucoadhesive oral formulation. NoviThera’s news focuses on preclinical psoriasis research and animal efficacy studies involving a monoclonal antibody approach.
In addition to scientific and development milestones, Nordicus publishes corporate and financing news. Examples include private placements of restricted common stock reported in Form 8-K filings, an application to uplist its shares from the OTCQB Market to the Nasdaq Capital Market, and changes to its Board of Directors. These items provide insight into how Nordicus funds and governs its portfolio of life sciences assets.
Investors and observers can use the NORD news page to track the evolution of Nordicus’ pipeline in periodontitis, oral leukoplakia, and psoriasis, as well as its corporate finance and listing plans. Regularly reviewing this page offers a consolidated view of scientific, regulatory, and capital markets developments connected to Nordicus and its subsidiaries.
Nordicus Partners (OTCQB: NORD), a financial consulting firm, has signed a Consultancy Agreement with Danish biopharmaceutical company BIO-CONVERT. BIO-CONVERT specializes in developing treatments for oral leukoplakia, a potentially cancerous condition. The partnership aims to help BIO-CONVERT establish a U.S. market presence. CEO Henrik Rouf expressed optimism about the collaboration and potential equity investment in BIO-CONVERT. BIO-CONVERT's innovative drug, QR-02, uses advanced technology for precise treatment of oral leukoplakia, potentially preventing oral cancer. The company plans a pilot efficacy study for QR-02.
Nordicus Partners , along with its 95% owned subsidiary Orocidin A/S, announced new insights into the treatment of periodontitis via their preclinical product QR-01. QR-01 is aimed at treating bacterial infections and normalizing immunological functions in periodontitis patients. The product has antimicrobial, immunomodulatory, and antibiofilm properties. It is formulated in a thermosensitive gel that solidifies at mouth temperature, allowing bi-weekly administration. Orocidin plans to start clinical trials for QR-01 in Q4, 2024.
Nordicus Partners (OTCQB: NORD), a financial consulting firm, has appointed Peter Severin as Chairman of the Board of Directors. Severin replaces Christian Hill-Madsen, who resigned to focus on developing periodontitis therapies for Orocidin A/S, a company predominantly owned by Nordicus. CEO Henrik Rouf expressed confidence in Severin’s extensive sales experience in the Nordic life sciences sector, which is expected to benefit Nordicus's strategy of acquiring majority stakes in Nordic and U.S. life sciences companies.
Nordicus Partners (OTCQB: NORD) has acquired a 95% stake in Orocidin A/S as of May 15, 2024. The company has also engaged FORCE Family Office to enhance investor awareness. FORCE will help Nordicus by promoting its story to a vast network of family offices, foundations, and endowments through webinars and events. CEO Henrik Rouf expressed optimism about working with FORCE to attract sophisticated Life Sciences investors. Steven Saltzstein, CEO of FORCE, praised Nordicus for connecting top Nordic scientists with the U.S. capital market, expecting significant value creation from this collaboration.
Nordicus Partners (OTCQB: NORD) has acquired a 95% stake in Orocidin A/S, a clinical-stage biopharmaceutical company specializing in periodontitis therapies, for $38 million. The transaction involves issuing 38 million restricted common shares to Orocidin’s shareholders. As a result, Nordicus CEO Henrik Rouf and Director Henrik Keller will join Orocidin's Board of Directors. This acquisition aligns with Nordicus's strategy to support innovative life sciences companies in entering the U.S. market. Orocidin’s key product, QR-01, is designed to combat periodontitis, addressing a significant unmet need in a market projected to reach $1.3 billion by 2029.
Nordicus Partners (OTCQB: NORD) has announced its uplisting to the OTCQB, a recognized public securities market by the SEC. This move aims to enhance liquidity, achieve fair valuation, and attract a wider network of investors and media partners. The uplisting is expected to aid in executing growth plans and making shares more appealing to potential targets.
Summary not available.
Summary not available.
Summary not available.